In this multicentre phase @ study , patients with clear cell metastatic renal cell carcinoma who received one previous VEGF-targeted therapy and one previous mTOR inhibitor were randomly assigned through an interactive voice and web response system to receive open-label dovitinib ( @ mg orally according to a @-days-on and @-days-off schedule ) or sorafenib ( @ mg orally twice daily ) in a @:@ ratio .